NeuroVoices: Brian Wainger, MD, PhD, on Ezogabine and Stem Cells in ALS
December 23rd 2020The assistant professor of neurology and anesthesiology at Harvard Medical School detailed the findings of a phase 2 trial using ezogabine, a drug once FDA-approved to treat epilepsy, in patients with ALS.
FDA Approves IncobotulinumtoxinA Pediatric Indication for Chronic Sialorrhea
December 22nd 2020There were no observations of clinical resistance or secondary treatment failure due to neutralizing antibodies, supporting the importance of the treatment’s unique purification process through XTRACT technology.
Reflections on the Impact of COVID-19: A Short Expert Series
December 21st 2020This specialty series is dedicated to assessing the impact COVID-19 has had on the quality of life of patients with neurological disorders and the clinicians who were forced to adapt during this unique era of medical history.
Jude Savarraj, PhD: Combination of Human Intuition and Machine Learning to Predict DCI
December 20th 2020The research scientist from the University of Texas Medical School discussed how machine learning was most effective in predicting delayed cerebral ischemia when it took human-derived variables into account.